Business
The US FDA approved LIB Therapeutics’ Lerochol (lerodalcibep), a PCSK9-inhibiting protein therapeutic injected once-monthly that does not require refrigeration, for adults with high cholesterol, including those with HeFH.
The bigger biopharma M&A deals seen particularly during the second half of 2025 should continue into 2026, PwC said, driven by LOEs and a more precision-driven process.
“We are not going back to Pasteur,” CEO Albert Bourla said, criticizing the US government’s current anti-vaccine rhetoric.
The big pharma’s 2026 revenue guidance of $59.5bn-$62.5bn is roughly flat with what is expected in 2025, and EPS guidance is below analyst expectations.
The France-based biotech is making solid progress amid mounting talk of a sale.
Regeneron epitomized best biotech practice by licensing its multi-blockbuster drugs to big pharma partners. Commercial success and the limitations of exclusivity have brought tensions to these relationships.
After buying the rights to Dren Bio’s lead candidate, DR-0201, in March, Sanofi has again tapped the start-up for a new drug discovery and development agreement for a potential new autoimmune therapy.
Despite recent setbacks in the field, big pharma still appears to have faith in the tau approach to Alzheimer's, as evidenced by Sanofi's new $1bn-plus deal with Korean venture ADEL for an early stage candidate.
Phase III results for gamma secretase inhibitor varegacestat in the treatment of desmoid tumors appear superior on both efficacy and safety to Merck KGaA’s Ogsiveo (nirogacestat).
With registrational Phase II data in Stiff Person Syndrome, Kyverna intends to file a BLA for mivocabtagene autoleucel in 2026. Longer term, it hopes to get the CAR-T approved for myasthenia gravis.
The nasal spray was approved by the US FDA as a rapid acting treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT).
Through its buyout of San Diego-based startup Arthrosi, Sobi gains the URAT1 inhibitor pozdeutinurad (AR882) for gout, which is an existing area of focus for the Swedish firm.
This week, a focus on key results from the American Society of Hematology meeting: Jaypirca headed for the front line; Kite’s Anito-cel in multiple myeloma; next-generation CAR-T approaches; Kelownia’s early in vivo CAR-T data; and Novartis’s ianalumab’s potential in ITP.
The US FDA approved Uplizna (inebilizumab) for generalized myasthenia gravis, an increasingly crowded market. Amgen believes it can compete due to the CD19-targeting antibody’s durable efficacy with twice-yearly dosing.
Arcus is ending development of its TIGIT-targeted antibody domvanalimab after it was determined a Phase III study would not show a survival benefit in gastrointestinal cancers.
The Switzerland-based group’s alpha-synuclein-targeted immunotherapy shows promise in slowing progression of the degenerative brain condition.
Merck & Co.’s checkpoint inhibitor Keytruda remains the best-selling drug worldwide. The top 10 products generated nearly $47bn in third-quarter revenues for big pharma, boosted by swelling sales of obesity drugs.
Having worked in stealth on its predictive computational R&D models, PsiThera has emerged to develop oral versions of blockbuster drug targets in inflammation and immunology.
Now in their 21st year, the Scrip Awards celebrated biopharma successes at the 2025 ceremony in London’s Mayfair, where AstraZeneca and Noubar Afeyan took home the top prizes.
Triple agonist retatrutide yielded 28.7% weight loss at 68 weeks, besting Zepbound’s Phase III data, while also showing benefit in knee osteoarthritis pain.